Navigation Links
Cempra Pharmaceuticals Names Carl Foster Executive Vice President of Business Development
Date:1/5/2011

fulfill the need for new and effective antibiotics. Solithromycin and TAKSTA have the potential to treat CABP and aBSSSI, respectively. I am excited about the products we have to offer and I look forward to helping Cempra bring these two products to market."  

About Cempra PharmaceuticalsFounded in 2006, Cempra Pharmaceuticals is a privately-held, clinical-stage pharmaceutical company focused on developing antibacterials to address critical medical needs. Two lead products, both in late-stage clinical trials, address the urgent and increasing need for new treatments targeting drug-resistant bacterial infections in the hospital and in the community. Cempra is well-funded and is committed to developing commercially and medically differentiated and novel products that reduce development risk and provide a high financial return. The company is also utilizing its proprietary compound library and chemistry technology to develop novel macrolides without antibacterial activity for non-antibiotic uses such as COPD, chronic inflammatory and GI disorders. Additional information about Cempra can be found at www.cempra.com.Media Contacts:Russo Partners, LLCRobert E. Flamm, Ph.D.(212) 845-4226 Robert.flamm@russopartnersllc.com Tony Russo, Ph.D.(212) 845-4251Tony.russo@russopartnersllc.com
'/>"/>

SOURCE Cempra Pharmaceuticals
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Cempra Pharmaceuticals Names Richard Kent, M.D., to Its Board of Directors
2. Cempra Pharmaceuticals to Present at the UBS Global Life Sciences Conference
3. Cempra Pharmaceuticals to Present at the Piper Jaffray 21st Annual Health Care Conference
4. Cempra Pharmaceuticals To Present at the Lazard Capital Markets 6th Annual Healthcare Conference on November 17th
5. Presentations of Cempra Pharmaceuticals CEM-102 (fusidic acid) at the Infectious Diseases Society of America Annual Meeting Highlight Properties That Make It an Excellent Anti-MRSA Candidate
6. Data Presented on Cempra Pharmaceuticals CEM-101 at the Infectious Diseases Society of America Annual Meeting Reinforces Potency and Coverage Against Multidrug-Resistant S. Pneumoniae Isolates
7. Jazz Pharmaceuticals to Present at the J.P. Morgan Healthcare Conference in San Francisco on January 12
8. MAP Pharmaceuticals to Present at the 29th Annual J.P. Morgan Healthcare Conference
9. Lexicon Pharmaceuticals to Present at the 29th Annual JPMorgan Healthcare Conference
10. Anadys Pharmaceuticals Initiates Phase IIb Study of ANA598 in HCV Patients
11. Optimer Pharmaceuticals Receives Orphan Drug Designation for Fidaxomicin for the Treatment of Pediatric Clostridium difficile Infection
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, ... OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE ... JURISDICTION AbbVie (NYSE: ABBV ) today announced financial ... "This was another very strong quarter for AbbVie, ... original guidance and announced plans to merge with Shire, a ...
(Date:7/25/2014)... N.Y. , July 25, 2014 /PRNewswire-iReach/ -- Dr. ... clinic, GPM Pediatrics, reacts to a recent study, which ... Photo - http://photos.prnewswire.com/prnh/20140723/129709 ... exposed to severe stress are more likely than others to ... months before pregnancy." There were two specific types ...
(Date:7/24/2014)... July 24, 2014  Parnell Pharmaceuticals Holdings Ltd ... will be added to Parnell,s already extensive pipeline ... Ltd, a biotechnology company. The compounds now known ... promise in bone regeneration and dermal regeneration, respectively. ... compounds for the veterinary market with the potential ...
Breaking Medicine Technology:AbbVie Reports Second-Quarter 2014 Financial Results 2AbbVie Reports Second-Quarter 2014 Financial Results 3AbbVie Reports Second-Quarter 2014 Financial Results 4AbbVie Reports Second-Quarter 2014 Financial Results 5AbbVie Reports Second-Quarter 2014 Financial Results 6AbbVie Reports Second-Quarter 2014 Financial Results 7AbbVie Reports Second-Quarter 2014 Financial Results 8AbbVie Reports Second-Quarter 2014 Financial Results 9AbbVie Reports Second-Quarter 2014 Financial Results 10AbbVie Reports Second-Quarter 2014 Financial Results 11AbbVie Reports Second-Quarter 2014 Financial Results 12AbbVie Reports Second-Quarter 2014 Financial Results 13AbbVie Reports Second-Quarter 2014 Financial Results 14AbbVie Reports Second-Quarter 2014 Financial Results 15AbbVie Reports Second-Quarter 2014 Financial Results 16AbbVie Reports Second-Quarter 2014 Financial Results 17AbbVie Reports Second-Quarter 2014 Financial Results 18AbbVie Reports Second-Quarter 2014 Financial Results 19AbbVie Reports Second-Quarter 2014 Financial Results 20AbbVie Reports Second-Quarter 2014 Financial Results 21AbbVie Reports Second-Quarter 2014 Financial Results 22AbbVie Reports Second-Quarter 2014 Financial Results 23AbbVie Reports Second-Quarter 2014 Financial Results 24AbbVie Reports Second-Quarter 2014 Financial Results 25AbbVie Reports Second-Quarter 2014 Financial Results 26AbbVie Reports Second-Quarter 2014 Financial Results 27AbbVie Reports Second-Quarter 2014 Financial Results 28AbbVie Reports Second-Quarter 2014 Financial Results 29AbbVie Reports Second-Quarter 2014 Financial Results 30AbbVie Reports Second-Quarter 2014 Financial Results 31AbbVie Reports Second-Quarter 2014 Financial Results 32AbbVie Reports Second-Quarter 2014 Financial Results 33AbbVie Reports Second-Quarter 2014 Financial Results 34AbbVie Reports Second-Quarter 2014 Financial Results 35AbbVie Reports Second-Quarter 2014 Financial Results 36
(Date:7/25/2014)... (PRWEB) July 25, 2014 Parkulture ... co-founders, professional stuntman and parkour instructor, Jared “JJ” Woods, ... sports competition show, American Ninja Warrior. The show will ... at 9PM and will rerun on the new Esquire ... a long-time Miami resident, has been balancing careers as ...
(Date:7/25/2014)... 2014 The new report “Carbohydrase ... Pharmaceuticals and Others), by Type (Amylases, Cellulases, and ... - Global Trends & Forecasts to 2019", by ... the global Carbohydrase market with analysis of trends, ... segmented and values are forecasted on the basis ...
(Date:7/25/2014)... NJ (PRWEB) July 25, 2014 CarePoint ... Dr. Edward Boylan, has joined our network, CarePoint ... the community. Hundreds of highly skilled and experienced physicians ... top doctors and practices in Hudson County, representing a ... Health’s commitment to provide the highest quality care to ...
(Date:7/25/2014)... In today’s technological era, every organization ... devices. This benefits the organization in various ways. But ... which can destroy the confidential information and processes of ... Compliance (EGRC) manage and protect the enterprise from various ... loss in dollars to the comp may. The equipment's ...
(Date:7/25/2014)... Eye & Vision has announced the celebration ... by expanding a new specialized ocular and vision service ... clinic. , By acquiring specialized Visual Evoked Potential (VEP) ... problems, patients with vision loss in need of visual ... implementation of this specialized vision testing clinic. The new ...
Breaking Medicine News(10 mins):Health News:Jared “JJ” Woods Prepares for American Ninja Warrior City Finals 2Health News:Jared “JJ” Woods Prepares for American Ninja Warrior City Finals 3Health News:Carbohydrase Market worth $3,717.7 Million by 2019 - Report by MarketsandMarkets 2Health News:Carbohydrase Market worth $3,717.7 Million by 2019 - Report by MarketsandMarkets 3Health News:Carbohydrase Market worth $3,717.7 Million by 2019 - Report by MarketsandMarkets 4Health News:Dr. Boylan Joins CarePoint Health Medical Group 2Health News:North America Enterprise Governance, Risk, and Compliance Market is Expected to Reach $3,972.6 Million in 2018 - New Report by MicroMarket Monitor 2Health News:North America Enterprise Governance, Risk, and Compliance Market is Expected to Reach $3,972.6 Million in 2018 - New Report by MicroMarket Monitor 3Health News:North America Enterprise Governance, Risk, and Compliance Market is Expected to Reach $3,972.6 Million in 2018 - New Report by MicroMarket Monitor 4Health News:North America Enterprise Governance, Risk, and Compliance Market is Expected to Reach $3,972.6 Million in 2018 - New Report by MicroMarket Monitor 5Health News:North America Enterprise Governance, Risk, and Compliance Market is Expected to Reach $3,972.6 Million in 2018 - New Report by MicroMarket Monitor 6Health News:Eye & Vision, a Leading Eye Doctor Group in Richardson, Celebrate Milestone and Expand Scope of Specialized Eye Care 2Health News:Eye & Vision, a Leading Eye Doctor Group in Richardson, Celebrate Milestone and Expand Scope of Specialized Eye Care 3
... Artery-opening procedure can be done up to 21 hours later ... (HealthDay News) -- Many people who arrive at hospital emergency ... hours for artery-opening angioplasty, even if an electrocardiogram (EKG) shows ... , There was no significant difference in key measures of ...
... , , CARDIFF, Calif., Sept. 1 ... ( http://www.jedimindinc.com ) announced today that their Medical ... for patients in wheelchairs. An estimated 1.6 million Americans residing ... National Health Interview Survey on Disability (NHIS-D). Jedi Mind,s Medical ...
... , , ATLANTA, Sept. 1 ... 50 schools across the U.S. with $2,000 ... ING Run For Something Better School Awards Program, financial ... for Sport and Physical Education (NASPE), is helping to ...
... Less invasive procedure shaves off lesions, researchers say , ... the esophagus can be treated effectively by less invasive, ... This is good news, as esophageal cancer arising from ... other cancer in the United States, and 90 percent ...
... Angeles, London, New Delhi, Singapore and Washington DC (1 ... and professional publisher is delighted to announce a new ... their official journal, Cephalalgia . Now in ... forum for original research papers, review articles and short ...
... available in French . , Montreal, ... autoimmune disorders which cause muscular inflammation are at increased ... Montreal researchers. Dr. Christian A. Pineau and his team ... Centre (RI-MUHC) have linked muscular inflammation to increased cardiovascular ...
Cached Medicine News:Health News:Sometimes Angioplasty Can Wait 2Health News:Jedi Mind Medical Applications Division to Concentrate on Wheelchair Mobility Applications 2Health News:ING Awards $100,000 in Grants to Combat Childhood Obesity 2Health News:ING Awards $100,000 in Grants to Combat Childhood Obesity 3Health News:ING Awards $100,000 in Grants to Combat Childhood Obesity 4Health News:ING Awards $100,000 in Grants to Combat Childhood Obesity 5Health News:New Therapy Spares Organ in Early Esophageal Cancer 2Health News:SAGE to publish leading international headache journal Cephalalgia 2Health News:Researchers link inflammatory diseases to increased cardiovascular risk 2
... adjusted for perfect focus where it's needed ... This, along with Keeler's wide angle light ... the patient's pupil size, you will see ... Lithium-ion technology provides a longer life battery ...
... adjusted for perfect focus where it's needed ... This, along with Keeler's wide angle light ... the patient's pupil size, you will see ... Lithium-ion technology provides a longer life battery ...
... Keeler ophthalmoscopes are individually adjusted for ... the eye, not on paper. This, along ... infinity focus, ensures that whatever the patient's ... and largest field of view. Lithium-ion technology ...
The Beta 200S combines Heine's patented aspherical optics (U.S. Pat. 4.963.014) and a single-step Rekoss disk with a range of 36 to +38 dpt. to provide perfectly-focused images even in cases of high ...
Medicine Products: